Affimed NV (AFMD)

[TheFinalCD]

03/08/2024 19:50:00 AFMD Affimed N.V. NASDAQ
T1

Affimed Announces 1-for-10 Reverse Stock Split $AFMD https://t.co/Sv8BHKrfBu

— Health Stocks News (@health_stocks) March 6, 2024

[Renee]

AFMD: effective March 11,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

[glenn1919]

AFMD......................................https://stockcharts.com/h-sc/ui?s=AFMD&p=W&b=5&g=0&id=p86431144783

[Invest-in-America]

AFMD: A town in Nevada named after a RACE HORSE!!!??? (LOVE-IT!!!!)




"You better STOP that kind of DANCING, Mister!!! Or I will phone HOMELAND DEFENSE!!!"

[Triple nickle]

One more good news release and this rockets to 1.35 and better

[befast]

Unfortunately in the wrong direction. If a rather positive presentation causes a 20+% decrease in share price, imagine what would happen with a negative one. You either stay silent or provide better narrative to rest your case. AFMD management should step in if they believe the presentation was not duly understood

[Triple nickle]

Adding it’ll go

[LowFloatLopes]

In at .3795

[Monksdream]

AFMD new 52 week low

[Monksdream]

AFMD new 52 week low

[Monksdream]

AFMD new 52=week low

[Monksdream]

AFMD new 52/week low

[mrplmer]

ASCO starts today. Looking forward to CC tomorrow at 6pm.

[mrplmer]

We go over $1 today.

[NY1972]

NK is a slow cooker looking at MDACC data. It takes a lot of convincing before it starts killing, unlike CART. None has died on auto and allo NK as many claimed.

[jondoeuk]

I am worried about the potential for on-target, off-tumour toxicities as the target is expressed by a number of healthy cells, including HSCs.

[NY1972]

CD123 is found in CSCs, which are not effectively eliminated by chemotherapy, have the capacity to self-renew, and are capable recapitulating disease. Thus, approaches to target are highly sought and have been tested in preclinical and clinical settings.

[NY1972]

CD123 is found in CSCs, which are not effectively eliminated by chemotherapy, have the capacity to self-renew, and are capable recapitulating disease. Thus, approaches to target are highly sought and have been tested in preclinical and clinical settings.

[jondoeuk]

Why CD123? https://finance.yahoo.com/news/affimed-announces-first-patient-successfully-103000071.html

[mrplmer]

Really. Not my experience.

[turning stone]

Everyone have a happy, healthy and prosperous NEW YEAR



GO AFMD!!!!!!!! 2023 is yours for the asking

[turning stone]

Okay it is time for more shareholders to get on this board and rally for a major up swing. All the signs show an upswing is here.

[turning stone]

There was really NO need for the share price to crash. Even two major analyst agree and moved up the stocks upward value. 65% percent of the open float is owned by institutions who don't seem to have a clue about this company. This is great news for me as I will keep buying more shares as the share price tumbles. I thought the German people were very smart I guess not. We shall see.

[mrplmer]

oh boy it works

[jjr04001]

Bounce coming $AFMD

[stockguard]

Post # 278 below please do not open the PDF file. Someone added some malware to it so DO NOT CLICK ON IT. Sorry that a jerk had to ruin the link.

[Steady_T]

[mrplmer]

When is the next event that could move this stock?

[stockguard]

Equity Research
Company Update — December 2, 2021
Biotechnology A?med NV (AFMD)
AFMD: Virtual NDR Highlights Unique Technology, Pipeline Depth, Breadth and Near-Term Value Drivers

https://www.docdroid.net/A28l2M1/wells-fargo-afmd-research-12-2-21-1-pdf

[stockguard]

Affimed: A small-cap biotech with room to run
Bucking the downward trend in biopharma in 2021, Affimed, a small-cap cancer immunotherapy company, has seen its shares actually rise by a healthy 19.8% this year. This tiny immunotherapy company has been able to swim against the current this year due to some truly eye-catching clinical trial data.

Last week, Affimed reported that its lead product candidate AFM13, when combined with a dose of natural killer cells, produced a 100% objective response rate in heavily pre-treated patients with recurrent or refractory CD30-positive lymphomas. AFM13 is thus on track to become the go-to therapy for later-line CD30-positive lymphomas; an indication that ought to be worth around $500 million to $600 million in sales per year.

To put these extremely preliminary revenue figures into context, Affimed currently sports a market cap of just $834 million. That's the key reason why Wall Street thinks this stock could more than double in value over the next 12 months.

Despite its relatively strong year, Affimed's novel anti-cancer platform still comes off as grossly undervalued at these levels. The company could eventually generate billions in sales and it stands out as a top buyout target right now.
https://www.fool.com/investing/2021/11/28/3-best-biopharma-stocks-to-buy-during-this-industr/

[mrplmer]

Buyout coming soon. Pòtential 10B market.

[stockguard]

Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study
Nov. 22, 2021 7:43 AM ETAffimed N.V. (AFMD)By: Mamta Mayani
Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (ICE) AFM13.
As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13.
As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses.
100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13.
No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed.
Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13.

https://seekingalpha.com/news/3773189-affimed-stock-jumps-18-after-reporting-100-orr-in-phase-1-2-lymphoma-study

[mrplmer]

A bump.

[Lynx5100]

Lol What do you call the day before yesterday

[mrplmer]

Need a breakout.

[stockguard]

Below post on conference was canceled.
Members, Thank you very much for your interest. Our sincere apologies but the doctor has a patient emergency, and we will need to reschedule this call. We will keep you posted. Thank you, Slingshot Insights

[stockguard]

This one could be interesting for a novice and also the informed, plus it states "AFMD CALL IS FREE FOR ALL" and you are able to add questions before the call. I joined the call that will be in about 2 hours Pacific time-01:00 PM PDT-AFMD-Understanding the potential of AFM13 + NK Cells in CD30-positive lymphomas. Interview Goal
This conversation will discuss the current standard of care for lymphoma patients and the potential of AFM13. We'll ask how meaningful CRs are for patients who failed multiple lines of prior therapies, durability expectations for responses, and what line AFM13 might fall if successful. Sign up below: https://mailchi.mp/slingshotinsights/4-calls-today-on-si-bvhn-jnj-hospital-rev-cycle-cms-patient-surveys-1990719
mailchi.mp
4 Calls Today on SI: NVS, CRIS, CCXI & AFMD (Free to Join)

[stockguard]

This morning AFMD Affimed initiated with a Buy at Truist
Truist analyst Srikripa Devarakonda initiated coverage of Affimed with a Buy rating and $10 price target. The analyst cites the company's phase 1 proof of concept data in two rare blood cancers, along with "futility hurdle" that Affirmed passed in pivotal trials, both of which support a peak sales opportunity of about
$500M. Devarakonda further notes the potential near-term upside for Affirmed from updated data from lead drug + NK cell combo likely to be presented at ASH2021.

[mrplmer]

Anyday now when it goes to $50 I am pretty sure youll be sorry you didnt follow my advise. Nuff said. They arent chasing amyloid plaçque. Sigmar1 receptor hold the key to CNS. Bye bye.

[stockguard]

mrplmer

Alzheimer's is way to speculative for any company at this stage so I would take a pass on the stock this early on but appreciate the heads up. My father-in-law just was diagnosed with Alzheimer's and I wish there was a biotech play seriously close to some relief for those sufferers and their families.
I follow biotech and invest in the space heavily, so I stay on top of a wide range of bio`s. But Alzheimer's biotech research has not reached that investable point for me yet as there still is too much downside risk in the smaller bio`s research. GLTY with Anavex

[mrplmer]

If you are not "in" on Anavex then ya better find some powder. They might just have the cure for many CNS diseases. Their Blacarsimine is safe effective and works on Rett syndrome Parkinson's Disease and Dementia. Readouts in the next 2 months. Alzheimer's readout 2nd Q 2022. It agonizes the Sigmar1 receptor and creates cellular homeostasis. IT will be huge. Due Diligence important.

[stockguard]

From below post:
Affimed: A new way to engage the immune system
Cancer immunotherapy has revolutionized the way oncologists approach the treatment of numerous liquid and solid tumors. Even so, the first generation of checkpoint inhibitors and genetically modified cellular therapies is far from 100% effective. Some of these novel treatments also come with a host of serious and potentially life-threatening side effects that limit their use in certain patient populations.

Affimed, a small-cap immunotherapy company, is trying to change this narrative by engaging the body's own immune system with a platform consisting of so-called "bi-specific antibodies" that active natural killer cells to attack tumor cells.

While the early stage results of the company's lead candidate, known as AFM13, have been impressive as a monotherapy from both an efficacy and safety standpoint, Affimed is also evaluating this therapy in combination with cord blood-derived natural killer cells, as well as checkpoint inhibitors. Wall Street, for its part, thinks this single biologic therapy could rake in well over $600 million at its peak.

Where do things stand now? Affimed is hoping to file its first regulatory application for AFM13 as a monotherapy indicated for patients with relapsed/refractory peripheral T-cell lymphoma. If things go according to plan, the biotech's first therapy could be on the market by perhaps 2023. Before then, however, there is a strong possibility that Affimed simply gets bought out. Big pharma has been on the hunt of late for early-stage cancer immunotherapy companies with unique assets, and Affimed fits that mold to a tee.

All told, Affimed's shares appear to be a downright steal at these levels. The company's market cap of $707 million arguably doesn't properly represent the promise of its anticancer platform -- even on a risk-adjusted basis. Affimed, after all, has already presented strong early stage results for its novel immunotherapy platform. Another major clinical update is reportedly slated to happen at a medical conference in the fourth-quarter of this year, according to the company's last quaterly update. Aggressive investors, therefore, might be wise to consider buying this undervalued biotech stock soon.
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/

[stockguard]

2 Biotech Stocks Set to Go Supernova Soon
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/

[stockguard]

Affimed (NASDAQ:AFMD) Receives $13.75 Average PT from Brokerages
Posted by Max Byerly on Jul 26th, 2021
Affimed (NASDAQ:AFMD) has been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.75.
https://www.tickerreport.com/banking-finance/7687643/affimed-nasdaqafmd-receives-13-75-average-pt-from-brokerages.html

[stockguard]

Advancing Immuno-Oncology by believing in the potential of the immune system to restore patients’ innate ability to fight cancer

https://www.rdworldonline.com/advancing-immuno-oncology-by-believing-in-the-potential-to-restore-patients-ability-to-fight-cancer/

[stockguard]

Affimed: Remaining Bullish Despite Study Discontinuation
https://seekingalpha.com/article/4438388-affimed-remaining-bullish-despite-study-discontinuation

[stockguard]

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2021 Results - Earnings Call Transcript
https://seekingalpha.com/article/4437496-affimed-n-v-afmd-ceo-adi-hoess-on-q1-2021-results-earnings-call-transcript

[stockguard]

$AFMD June presentation https://www.affimed.com/wp-content/uploads/Affimed-N.V._CP_June-2021.pdf

[stockguard]

Wells Fargo Says
Affimed is an immune-oncology researcher in the biopharma world, looking into new therapies for cancer patients. The company’s ‘redirected optimized cell killing’ (ROCK) platform is used to develop innate cell engagers capable of reactivating the patient’s own immune cells to combat tumors. The company has 6 separate programs in its development pipeline, most in the preclinical stage of research. The company’s focus is on the treatment of hematological and solid tumors.

Of Affimed’s drug candidates, AFM13 is the first to have reached the clinical trial stage. The candidate has trials ongoing for the treatment of peripheral T cell lymphoma and CD30-postive T cell lymphoma, as well as transformed mycosis fungoides. Other lines of research are in earlier phases of development. AMF13 is a CD16A-based innate cell engager, and has shown promise of some therapeutic efficacy as well as a favorable safety profile.

In March, Affimed announced that it will be continuing REDIRECT, a Phase 2 study of AFM13 as a treatment for CD30-postivie T cell lymphoma. So far, the study has shown some anti-tumor response in both Cohort A and Cohort B of the patient base. Affimed’s recent program update also showed significant progress with AFM24, the company’s second most advanced program, now in a Phase 1 trial of its efficacy against solid tumors.

In his report on Affimed for Well Fargo, analyst Nick Abbott gives the stock an Overweight (i.e. Buy) rating and a $18 price target that indicates a potential for 62% upside in the year ahead.

Backing his stance, Abbott writes, “Our Overweight rating on AFMD reflects our view on AFMD’s approach to immuno-oncology (IO) with focus on the ROCK platform of innate cell engaging bispecific antibody development as a monotherapy, in combination with checkpoint inhibitors and in combination with cell therapy. Positive interim analysis of the registration-directed REDIRECT trial of AFM13 provides validation of the ROCK platform, in our view.”

Wall Street’s analysts are unanimous here, giving the stock 5 positive reviews in recent weeks for a Strong Buy consensus rating. The shares are priced at $10.42 and their $14 average target implies ~25% one-year upside.
https://www.tipranks.com/news/article/wells-fargo-says-these-2-stocks-could-spike-over-60-from-current-levels

[stockguard]

AACR 2021 – Affimed wins, Oncternal loses
https://www.evaluate.com/vantage/articles/events/conferences/aacr-2021-affimed-wins-oncternal-loses?mkt_tok=NjA3LVlHUy0zNjQAAAF8W1QPkVSAPbWmLhUbrR4idI6XHuI4qqQNsve0C1S0Z386uvhQ0wqI9rfYmu0HPw3VlDUrqT2crSKek60ZcLyAg24O5Tv2UWzZCDZWaNxs85YjIw